What is CDT Equity Inc. (CDT)?

CDT Equity Inc. (CDT) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CDT?

The current price of CDT is $0.08. Prices are updated in real time on Stocks360.

What is CDT's price-to-earnings (PE) ratio?

CDT's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is CDT's market capitalization?

CDT's market capitalization is $89,961.00, placing it in the small-cap tier.

CDT Equity Inc. (CDT)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.08

Market Cap

$89.96K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.56

Day Range

$0.08 – $0.10

52-wk Range

$0.08 – $20,125.00

Avg Volume

N/A

Volume

4.87M

CDT Equity Inc. (CDT) is a publicly traded company in the Healthcare sector. Latest price: $0.08. Market cap $89.96K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $19,250.00 2026-10-27 · $0.08 (-100.00%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About CDT Equity Inc.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.07×
EV / EBITDA	4.59×
EV / Sales	0.67×
Earnings Yield	213696.46%
Free Cash Flow Yield	-1438.40%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$970.66M
Revenue (TTM)	$1.45B
Net Income (TTM)	$192.24M
Free Cash Flow (TTM)	-$85.14M
Net Debt	$970.57M
Working Capital	$741.05M
Gross Margin	38.65%
Operating Margin	11.55%
Net Margin	6.30%
Return on Equity	9.26%
Return on Invested Capital	4.47%